Evestia Clinical (formerly EMAS Pharma), an independent global specialist Contract Research Organization (CRO), has acquired ICRC-Weyer GmbH, a Berlin-based CRO and scientific consultancy. The acquisition strengthens Evestia Clinical’s presence in Germany and Europe and further enhances the company’s full-service clinical research solutions for biotech innovators.

ICRC-Weyer offers experience in data-driven clinical research, with scientific and operational expertise in biostatistics, data management, and medical writing across the full clinical development cycle. Integrating these specialist capabilities expands the Evestia Clinical’s European presence and gives biotech innovators enhanced access to high-quality services that are increasingly critical as clinical trial development grows in complexity and regulatory expectations evolve. At the same time, ICRC-Weyer’s clients will benefit from access to Evestia Clinical’s full suite of global clinical trial services from Phase I-III and beyond, providing more integrated, end-to-end support across core therapeutic areas including oncology, neurology, and rare diseases.

Lewis Cameron, CEO of Evestia Clinical, said: “The acquisition of ICRC-Weyer is a targeted investment that strengthens Evestia Clinical’s operational delivery in Europe. Integrating ICRC-Weyer’s capabilities into our existing offering enhances the depth of support we provide to biotech innovators and enables more seamless, end-to-end clinical research solutions in complex, high-research therapeutic areas. With a strong presence in the United States through our integration with ARG, and now an established base in Europe with on-the-ground expertise in Germany complementing operations already established in Spain, Italy, and France, we are broadening our global footprint.”

Johann Daniel Weyer, Managing Director of ICRC-Weyer GmbH, said: “Joining Evestia Clinical is a natural step in ICRC-Weyer’s development. By combining ICRC-Weyer’s expertise in scientific consultancy and back-office CRO services with Evestia Clinical’s global reach and specialist therapeutic focus, we will offer clients a stronger and more comprehensive proposition as they navigate increasingly complex clinical development programs across Europe and beyond.”

Terms of the deal have not been disclosed. ICRC-Weyer will integrate with Evestia Clinical’s operations with no change to its services or teams and it will continue to operate under the ICRC-Weyer brand. Johann Daniel Weyer will join the Evestia Clinical leadership team, and all employees will transition as part of the agreement.

Other Pharma Industry Acquisitions

Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.